J&J suing Samsung Bioepis over Stelara biosimilar (update)
Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...
India West3h
US Drugmaker Amgen To Invest $200 Million In India
NEW DELHI – U.S. drugmaker Amgen plans to invest approximately $200 million this year in its new technology center located in ...
J&J sues Samsung Bioepis over Stelara biosimilar
Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...
The Pharma Letter9h
Amgen presses on with Indian site with $200 million 2025 investment
US biotech major Amgen will invest about $200 million this year in its new technology center in southern India.
The Litigators on The American Lawyer’s Top Lateral Hires List
With only four litigation hires making Am Law’s top 25 for this year, firms appear to be gearing up for the expected ...
ARY News Live12h
Amgen to invest $200 million in India
US drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further ...
J&J sues Samsung Bioepis over contract breach for Stelara biosimilar
J&J said it is seeking a preliminary injunction for Samsung Bioepis' close copy of Stelara over an unauthorized sublicense ...